This trial is evaluating whether Ibrutinib will improve 1 primary outcome and 6 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented, assessed up to 5 years.
This trial requires 41 total participants across 1 different treatment group
This trial involves a single treatment. Ibrutinib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"In the United States, most lymphomas are non-Hodgkin's lymphoma originating in B Cell lineage, and the majority are diffuse large cell non-Hodgkin's lymphoma (accounting for about 40% of all lymphomas). The most common underlying causes of non-Hodgkin's lymphoma are infection with high-grade B cells, including chronic lymphocytic leukemia, and smoking. The most common cause of follicular lymphoma is follicular non-Hodgkin's lymphoma.\n\nThere are various risk factors associated with lymphoma." - Anonymous Online Contributor
"Patients with lymphoma are treated with chemotherapy for several weeks, and patients with follicular lymphoma usually receive treatments for six or more months, which may include immunotherapy, radiotherapy, or surgery." - Anonymous Online Contributor
"This report offers another argument for active treatment of indolent lymphomas, even though they may persist for an extended period. Lymphomas are probably curable by careful, local treatment if the disease is restricted to the lymph nodes near the original site of disease." - Anonymous Online Contributor
"Lymphoma, follicular, is a disease that begins in the B lymphocytes and spreads to another part of the body. It can cause weight loss, blood problems, fatigue, and feeling sick; it can be caused by or be associated with certain cancers, autoimmune disorders, or viral infections. Lymphoma, follicular, is typically found in older people; it is diagnosed by a doctor using blood tests, scans, or other tests to assess tissue in the body. The disease was first described in 1852." - Anonymous Online Contributor
"Many signs and symptoms of lymphoma are nonspecific. People with lymphoma sometimes present without detectable symptoms, while a person with nonlymphoma lymphadenopathy can have nonspecific presentations." - Anonymous Online Contributor
"About 30,000 people will be diagnosed with histiocytic and B cell lymphoma in 2006 in the US. Those with lymphoma may be diagnosed in the more than one year after the diagnosis of rheumatic disease even if there is a chronic form of arthritis/arthralgia. Therefore, it is important for physicians to think of autoimmune syndromes in their differential diagnosis in their patients with autoimmune diseases and lymphoma in particular." - Anonymous Online Contributor
"Ibrutinib in combination with paclitaxel had a low rate or serious side effect rates (<5%). A significant fraction of patients who experienced any serious side effect dropped from the study early. The most common side effects were infection, anemia, rash and/or itch. Less common, but more common than serious, side effects were neutropenia, peripheral edema, diarrhea and fatigue. One-half of the patients had to decrease their dosage of ibrutinib as a result of side effects." - Anonymous Online Contributor
"The number of deaths from follicular lymphoma is low; over 90% of cases are diagnosed after death. The risk of death also varies with site of disease. The 5-year overall survival rate is 63%; the 5-year relapse-free survival rate is 58%. The major prognostic factors were patient age at diagnosis, number of involved sites, stage of disease and initial treatment. We recommend that patients of all age groups with follicular lymphoma be treated with the standardized protocol recommended by the National Comprehensive Cancer Network." - Anonymous Online Contributor
"Lymphoma, follicular represents a challenge for treatment of disease that is currently devastating and unpredictable. Clinical trials are being done to identify new therapies. The treatment options currently available to patients with this disease are limited and the long-term outcome and prognosis are dismal. The development of new treatment strategies for lymphoma, follicular is essential." - Anonymous Online Contributor
"While it is not possible to state in exact terms the odds of lymphoma occurring at a given period, there is a greater likelihood of developing lymphoma if one is born with a history of immune suppression as a youngster. When looking at the risks, the most important factor is a person's age at the time of diagnosis. If one's diagnosis is made in the first 20 years of life, the one-year risk of developing lymphoma is approximately 40%. However, if diagnosis is made later in one's life, that same risk of developing non-Hodgkin's lymphoma is approximately 10%. Overall, about 7% of people with lymphoma develop it, of whom about 2% will develop the follicular type." - Anonymous Online Contributor
"This preliminary report from Phase I studies suggests that this ALK / PI3K inhibitor is well-tolerated as a single agent and can overcome both acquired and intrinsic resistance. Ibrutinib may therefore be useful in treating some patients who do not respond well to the FDA-approved kinase inhibitors with this common kinase pathway activated in many types of cancer." - Anonymous Online Contributor
"This phase II study with ibrutinib showed that ibrutinib and its metabolites effectively control progression of cutaneous T-cell lymphoma and the effects were superior to controls. Ibrutinib is highly effective in this disease, and thus warrants further investigation as a therapeutic option." - Anonymous Online Contributor